Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
It is hypothesized, that local retinoic acid (RA) homeostasis is functionally involved in the pathophysiology of depression. In a cross-sectional (and partly longitudinal) analysis, serum RA status will be assessed in healthy controls and subjects with Major Depression, Alzheimer's disease, alcoholism and in subjects with schizophrenia.
Retinoids comprise of a group of small-molecule derivatives of Vitamin A with retinoic acid (RA) representing the biologically most active endogenous form. RA has multiple functions central nervous system (CNS). It is hypothesized, that local RA homeostasis is functionally involved in the pathophysiology of numerous neuropsychiatric diseases.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MDD | Currently unmedicated patients with a depressive episode in the context of unipolar major depression | ||
| Control | Healthy Controls | ||
| Alzheimer's Disease | Patients with Alzheimer's disease | ||
| Alcoholism | Subjects with alcoholism | ||
| Schizophrenia | Subjects with before and schizophrenia prior to and during medication with clozapine, olanzapine or aripiprazole |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Serum retinoic acid (RA) levels [nM] | Serum retinoic acid levels [nM] as determined by HPLC according to previously published protocols | Week 0 |
| Measure | Description | Time Frame |
|---|---|---|
| For MDD group: MADRS | Questionnaire to assess symptom severity in MDD | Week 1, 3, 6 |
| For MDD group: BDI II | Self-rating to assess of symptom severity in MDD |
Not provided
MDD-Group
Inclusion Criteria:
Exclusion Criteria:
AD-Group
Inclusion Criteria:
Exclusion Criteria:
Schizophrenia-Group
Inclusion Criteria:
Exclusion Criteria:
Alcoholism-Group
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Out- and inpatients are eligible and will be recruited from patients seeking medical treatment at the Department of Psychiatry, Campus Benjamin Franklin, Charité, University Medicine Berlin.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julian Hellmann-Regen, MD | Contact | Julian.Hellmann@charite.de | ||
| Vera Clemens, MD | Contact | Vera.Clemens@charite.com |
| Name | Affiliation | Role |
|---|---|---|
| Isabella Heuser, MD, PhD | Chair: Department of Psychiatry, Charité, CBF | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Psychiatry, Charité - Campus Benjamin Franklin | Recruiting | Berlin | 12203 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D000544 | Alzheimer Disease |
| D000437 | Alcoholism |
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D003704 | Dementia |
Not provided
Not provided
Not provided
Not provided
Not provided
peripheral venous blood
| Week 1, 3, 6 |
| For MDD and schizophrenia Group: Change of serum retinoic acid (RA) levels [nM] | Serum retinoic acid levels [nM] as determined by HPLC according to previously published protocols | Week 1, 3, 6 |
| For schizophrenia group: Positive and Negative Syndrome Scale (PANSS) for Schizophrenia | Measurement of symptom severity of patients with schizophrenia | Week 1, 3, 6 |
| For schizophrenia group: Change of metabolic parametres For schizophrenia group:Positive and Negative Syndrome Scale (PANSS) | Assessmant of weight, blood pressure, levels of Glucose, HbA1c, cholesterols and dietry | Week 1, 3, 6 |
| D001927 |
| Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D024801 | Tauopathies |
| D019636 | Neurodegenerative Diseases |
| D019965 | Neurocognitive Disorders |
| D019973 | Alcohol-Related Disorders |
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |